Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.
Authors
Gregory Naylor
Beatson WOSCC, Glasgow, United Kingdom
Gregory Naylor , Alistair McLaren , Janet Graham , T.R. Jeffry Evans
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
DOI
10.1200/JCO.2022.40.4_suppl.390
Abstract #
390
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma.
First Author: Jamie Grossman
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.
First Author: Yoshinari Asaoka
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
First Author: Richard S. Finn
Poster
2021 ASCO Annual Meeting
CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis.
First Author: Jorg Trojan